Mereo BioPharma Group plc (LON:0A9G)

Market Cap	46.08M -87.1%
Revenue (ttm)	371.97K -50.0%
Net Income	-30.93M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,257
Average Volume	1,385,776
Open	0.4117
Previous Close	0.4117
Day's Range	0.3832 - 0.4232
52-Week Range	0.2666 - 3.1100
Beta	0.26
RSI	30.47
Earnings Date	Mar 26, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 36
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9G

Financial Performance

Financial numbers in USD